ALLUMIN8 gains FDA 510(k) clearance for A8 INTEGR8 porous pedicle screw system
Company clears first step of new “Therapeutic Hardware” spine‑fusion platform
U.S. medical‑device firm ALLUMIN8 reports that the A8 INTEGR8 Porous Pedicle Screw System has received 510(k) clearance from the U.S. Food & Drug Administration (FDA), marking the first step in the company’s broader strategy to merge advanced implant engineering with biologic integration.
ALLUMIN8 reports the A8 INTEGR8 system to be the first pedicle screw manufactured via additive (3D) printing in the 5.5 mm diameter size that has met the rigour required for FDA clearance.
According to the company, key engineering features include a proprietary “Cultiv8 Lattice” porous structure designed to mirror vertebral bone architecture, a patent‑pending “Screw Thread In‑growth” topography aimed at improved purchase and bone in‑growth, and an adapter system (A8 CIRCUL8™) for intra‑operative biologic delivery. However, the adapter is not yet cleared for U.S. sale.
Spinal fusion remains one of the most widely performed surgical interventions globally, yet complication and re‑operation rates remain elevated. According to analysis from the spine‑device sector, complication rates for spinal fusions range from approximately 21 % to 62 %, with pedicle‑screw loosening cited in 30 % to 54 % of cases.
ALLUMIN8 positions the A8 INTEGR8 screw as a response to the mechanical‑biological interface gap in spinal fixation: the goal is not only structural fixation but enhanced osseointegration and long‑term stability through the implant’s surface architecture and additive manufacturing approach.
With FDA clearance now in hand for the screw system, ALLUMIN8 reports that the next phase will involve commercial rollout (including international distribution) and subsequent regulatory clearances for complementary components of its “Therapeutic Hardware” platform. The company also said that the A8 CIRCUL8 bone‑marrow‑delivery adapter is next in line for regulatory submission.
